LB Pharmaceuticals, Inc. (LBRX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$38.09-6.76%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · LBRX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Exhibit 99.1 LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update Strengthened leadership with the appointment of Susan G.
Stated in 3 of 3 supplied quarters. Management reported: “Exhibit 99.1 LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update Strengthened leadership with the appointment of Susan G.” “For the nine months ended September 30, 2026, research and development expenses were $110.3 million, compared to $8.3 million for the nine months ended September 30, 2025.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not enough signal yet.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Exhibit 99.1 LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update Strengthened leadership with the appointment of Susan G.”
“Exhibit 99.1 LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial…”
“Exhibit 99.1 LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schi…”
The proceeds are intended to fund expansion of LB-102 into new indications, potentially including negative symptoms of schizophrenia and Alzheimer’s disease psychosis/agitation, and for general corpo…
Stated in 3 of 3 supplied quarters. Management reported: “The proceeds are intended to fund expansion of LB-102 into new indications, potentially including negative symptoms of schizophrenia and Alzheimer’s disease psychosis/agitation, and for general corporate purposes.” “Net proceeds were approximately $140.9 million, after deducting financial advisory fees and other financing expenses.”
“The proceeds are intended to fund expansion of LB-102 into new indications, potentially including negative symptoms of schizophrenia and Alzheimer’s disease psychosis/agitation, and for general corpo…”
“The proceeds are intended to fund expansion of LB-102 into new indications, potentially including negative symptoms of schizophrenia and Alzheimer’s disease psychosis/agitation, and for general corpo…”
“• Announced the further expansion of the LB-102 development program in mood disorders, with plans to initiate a Phase 2 trial in the adjunctive treatment of MDD in early 2027, with topline data expec…”
Based on current operating assumptions, the Company anticipates its current cash, cash equivalents, and short-term investments will support its planned operations beyond the second quarter of 2029.
Stated in 3 of 3 supplied quarters. Management reported: “Based on current operating assumptions, the Company anticipates its current cash, cash equivalents, and short-term investments will support its planned operations beyond the second quarter of 2029.” “Based on current operating assumptions, the Company anticipates its current cash, cash equivalents, and short-term investments will support its planned operations beyond the second quarter of 2029.”
“Based on current operating assumptions, the Company anticipates its current cash, cash equivalents, and short-term investments will support its planned operations beyond the second quarter of 2029.”
“Based on current operating assumptions, the Company anticipates its current cash, cash equivalents, and marketable securities will support its planned operations beyond the second quarter of 2029.”
“Based on current operating assumptions, the Company anticipates its current cash, cash equivalents, and marketable securities will support its planned operations into the second quarter of 2029.”
“We recently strengthened our leadership team with the appointments of Dr. Susan Kozauer as Chief Medical Officer and Joe Miller as Chief Financial Officer, adding two highly accomplished executives…
Stated in 1 of 3 supplied quarters. Management reported: ““We recently strengthened our leadership team with the appointments of Dr. Susan Kozauer as Chief Medical Officer and Joe Miller as Chief Financial Officer, adding two highly accomplished executives whose expertise is directly aligned with our next phase of growth as we advance LB-102 across multiple neuropsychiatric indications and prepare for potential commercialization in schizophrenia,” said Heather Turner, Chief Executive Officer of LB Pharmaceuticals.”
““We recently strengthened our leadership team with the appointments of Dr. Susan Kozauer as Chief Medical Officer and Joe Miller as Chief Financial Officer, adding two highly accomplished executives…”
Continue pivotal Phase 3 NOVA-2 trial in schizophrenia with topline data expected H1 2027 and plan pre-NDA FDA meeting in H2 2027; advance Phase 2 trials in bipolar depression and adjunctive MDD.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
10 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.